Rechallenge after Clozapine-Induced Neutropenic Events: A Case Series.

Clozapine is highly effective for resistant schizophrenia but limited by neutropenia concerns. In this 30-year series, 27 patients discontinued clozapine and 13 were rechallenged; 61.5% were successfully maintained. No fatalities occurred, and index-episode severity did not predict outcomes. Rechallenge appears safe when guided by individualised risk-benefit assessment.